3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. (September 2015) - Soria, J.C.; Goldman, J.W.; Wakelee, H.; Gadgeel, S.; Camidge, D.R.; Solomon, B.; Yu, H.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Perol, M.; Reckamp, K.; et al.